Benefits of Using Dapsone in Patients Hospitalized with COVID-19
Since the start of the SARS-CoV-2 pandemic, refractory and relentless hypoxia as a consequence of exuberant lung inflammation and parenchymal damage remains the main cause of death. We have earlier reported results of the addition of dapsone in this population to the standard of care. We now report...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/2/195 |
| _version_ | 1827652403212582912 |
|---|---|
| author | Badar A. Kanwar Asif Khattak Jenny Balentine Jong Hoon Lee Richard E. Kast |
| author_facet | Badar A. Kanwar Asif Khattak Jenny Balentine Jong Hoon Lee Richard E. Kast |
| author_sort | Badar A. Kanwar |
| collection | DOAJ |
| description | Since the start of the SARS-CoV-2 pandemic, refractory and relentless hypoxia as a consequence of exuberant lung inflammation and parenchymal damage remains the main cause of death. We have earlier reported results of the addition of dapsone in this population to the standard of care. We now report a further chart review of discharge outcomes among patients hospitalized for COVID-19. The 2 × 2 table analysis showed a lower risk of death or discharge to LTAC (Long term acute care) (RR = 0.52, 95% CI: 0.32 to 0.84) and a higher chance of discharge home (RR = 2.7, 95% CI: 1.2 to 5.9) among patients receiving dapsone compared to those receiving the usual standard of care. A larger, blinded randomized trial should be carried out urgently to determine if dapsone indeed improves outcomes in COVID-19. |
| first_indexed | 2024-03-09T20:54:59Z |
| format | Article |
| id | doaj.art-e0104b5da390449392ddce55bc7a90cc |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T20:54:59Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-e0104b5da390449392ddce55bc7a90cc2023-11-23T22:25:04ZengMDPI AGVaccines2076-393X2022-01-0110219510.3390/vaccines10020195Benefits of Using Dapsone in Patients Hospitalized with COVID-19Badar A. Kanwar0Asif Khattak1Jenny Balentine2Jong Hoon Lee3Richard E. Kast4Department of Intensive Care Unit and Neonatal Intensive Care, Hunt Regional Hospital, Greenville, TX 75401, USADepartment of Intensive Care Unit and Neonatal Intensive Care, Hunt Regional Hospital, Greenville, TX 75401, USADepartment of Intensive Care Unit and Neonatal Intensive Care, Hunt Regional Hospital, Greenville, TX 75401, USAScience and Research Center, Seoul National University College of Medicine, Seoul 03080, KoreaIIAIGC Study Center, Burlington, VT 05408, USASince the start of the SARS-CoV-2 pandemic, refractory and relentless hypoxia as a consequence of exuberant lung inflammation and parenchymal damage remains the main cause of death. We have earlier reported results of the addition of dapsone in this population to the standard of care. We now report a further chart review of discharge outcomes among patients hospitalized for COVID-19. The 2 × 2 table analysis showed a lower risk of death or discharge to LTAC (Long term acute care) (RR = 0.52, 95% CI: 0.32 to 0.84) and a higher chance of discharge home (RR = 2.7, 95% CI: 1.2 to 5.9) among patients receiving dapsone compared to those receiving the usual standard of care. A larger, blinded randomized trial should be carried out urgently to determine if dapsone indeed improves outcomes in COVID-19.https://www.mdpi.com/2076-393X/10/2/195ARDSCOVID-19dapsoneNLRP3 |
| spellingShingle | Badar A. Kanwar Asif Khattak Jenny Balentine Jong Hoon Lee Richard E. Kast Benefits of Using Dapsone in Patients Hospitalized with COVID-19 Vaccines ARDS COVID-19 dapsone NLRP3 |
| title | Benefits of Using Dapsone in Patients Hospitalized with COVID-19 |
| title_full | Benefits of Using Dapsone in Patients Hospitalized with COVID-19 |
| title_fullStr | Benefits of Using Dapsone in Patients Hospitalized with COVID-19 |
| title_full_unstemmed | Benefits of Using Dapsone in Patients Hospitalized with COVID-19 |
| title_short | Benefits of Using Dapsone in Patients Hospitalized with COVID-19 |
| title_sort | benefits of using dapsone in patients hospitalized with covid 19 |
| topic | ARDS COVID-19 dapsone NLRP3 |
| url | https://www.mdpi.com/2076-393X/10/2/195 |
| work_keys_str_mv | AT badarakanwar benefitsofusingdapsoneinpatientshospitalizedwithcovid19 AT asifkhattak benefitsofusingdapsoneinpatientshospitalizedwithcovid19 AT jennybalentine benefitsofusingdapsoneinpatientshospitalizedwithcovid19 AT jonghoonlee benefitsofusingdapsoneinpatientshospitalizedwithcovid19 AT richardekast benefitsofusingdapsoneinpatientshospitalizedwithcovid19 |